The DIRECTOR-GENERAL having regard to articles 8 and 9 of legislative decree July 30, 1999, # 300; Visto l'art. September 30, 2003, of Decree-Law 48 n. 269, converted into law November 24, 2003, n. 326, establishing the Italian medicines agency; Having regard to the Decree of the Minister of health in consultation with the Ministers for public administration and Economics and finance dated September 20, 2004, n. 245 laying down rules on the organisation and the functioning of the Italian Medicines Agency, pursuant to paragraph 13 of article. the aforementioned 48 as amended by order No. 53 of the Minister of health, in consultation with the Ministers for public administration and simplification and of economy and Finance of the March 29, 2012; Having regard to the Legislative Decree March 30, 2001, n. 165; Having regard to act July 15, 2002, # 145 having regard to the Decree of the Minister of health of November 8, 2011, recorded by the Central Office of the budget to the register "visas", sheet # 1282, dated November 14, 2011, with which he was appointed Director General of the Italian Medicines Agency. Luca Pani, as from November 16, 2011; Having regard to Decree-Law No 158 September 13, 2012, converted, with amendments by law November 8, 2012 # 189, containing "urgent provisions to promote the development of the country through a higher level of health protection and, in particular, article. 12, paragraph 5; Having regard to act December 24, 1993, no. 537 concerning "public finance corrective" with particular reference to art. 8; Visto l'art. 1, paragraph 40, December 23, 1996, law n. 662 on "rationalization measures of public finance", which identifies the margins of distribution for pharmaceutical companies, wholesalers and pharmacists; Visto l'art. 48, paragraph 33, November 24, 2003, law No. 326, which has negotiating the price for products reimbursed by authorisation holders between agency and S. N.; Having regard to the Legislative Decree of April 24, 2006, n. 219, published in the Gazzetta Ufficiale della Repubblica italiana n. 142 of June 21, 2006 on the introduction of Directive 2001/83/EC (and subsequent amending directives) on the Community code relating to medicinal products for human use and Directive 2003/94/EC; Having regard to the 1 February 2001 CIPE; View the determination October 29, 2004 "Notes AIFA 2004 (Revision Notes CUF)", published in the ordinary supplement to the official journal # 259 of November 4, 2004 as amended; View AIFA'S determination of July 3, 2006 published in the official journal, General series No 156 of July 7, 2006; View AIFA determination of September 27, 2006 published in the official journal, General series No. 227, September 29, 2006 concerning "maneuver for Government subsidized and non-subsidized pharmaceutical expenditure"; Given the decree by which the company Genzyme Therapeutics LTD is authorised the placing on the market of the medicinal product LEMTRADA; Having regard to the determination of 885/2014 August 18, 2014, n. pubblicata nella Gazzetta Ufficiale della Repubblica italiana n. 200 of August 29, 2014, on the classification of the medicinal product in accordance with art. 12, paragraph 5, reads November 8, 2012 # 189 of medicinal products for human use centrally approved; Having regard to the application with which the firm Genzyme Therapeutics LTD has applied for reclassification of the Pack code A.I.C. # 043027010 (s); Having regard to the opinion of the scientific and Technical Advisory Committee of June 9, 2014; Having regard to the opinion of the pricing and Reimbursement at its meeting of November 26, 2014; Having regard to resolution No. 1 of January 30, 2015 AIFA's Board of Directors adopted on the proposal of the Director General;
Determines Art. 1 Classification for the purposes of new listings is the medicine Lemtrada in packaging below is classified as follows: Pack: 12 mg-concentrate for solution for intravenous infusion-use-vial (glass)-1.2 ml (10 mg/ml)-1 vial-A.I.C. # 043027010/E (10) 1912L2 (based on 32);
New listings: class H;
Ex factory price (excluding VAT): €8,812.50;
Price (VAT included): €14,544.15. Validity of the contract: 24 months. Discount required to public facilities on the price Ex Factory as per contractual terms. For the purposes of the NHS prescriptions, users specifically identified by the regions, will have to complete the computerized data collection of enrollment indicating eligible patients and follow-up, applying negotiation conditions according to the guidelines that are published on the Agency website, web platform-to the address https://www.agenziafarmaco.gov.it/registri/which form an integral part of this determination. Pending the full implementation of the Register web-based monitoring, in order to ensure the availability of treatment to patients prescriptions must be made according to the criteria of eligibility and appropriateness prescriptive documentation available on the Agency's institutional Portal reported: http://www.agenziafarmaco.gov.it/it/content/registri-farmaci-sottopos ti-monitoring. The data relating to the processing operations carried out from the date of entry into force of this determination, through temporary mode above, should then be listed in the web platform, according to modalities which will be listed on the site: http://www.agenziafarmaco.gov.it/it/content/registri-farmaci-sottopos ti-monitoring.